


CVDPREVENT ANNUAL AUDIT REPORT 2025 - KEY FINDINGS

DATA UP TO 31ST MARCH 2025

HYPERTENSION

Key finding 1:


70.3% treated to Quality & Outcomes Framework (QOF) threshold, **2.7m** still not optimally managed.



Nearly 3 million patients with hypertension not treated to target.

Key finding 2:

Younger adults **less likely** to meet thresholds.



Working-age adults are **falling behind** in blood pressure control.

Key finding 3:



High BP




higher admissions & deaths

Patients with very high BP face **higher risk** of further complications, including heart attack, stroke and death.

CHOLESTEROL

Key finding 4:

56.7% of people at risk of CVD are on lipid-lowering therapy (**up 498k patients from 2024**). Uptake of lipid therapy is improving – but still only **just over half** of high-risk patients.



Key finding 5:

Less than half of CVD patients at cholesterol target.



Over 1.4 million CVD patients are not treated to NICE cholesterol target.

Key finding 6:

Persistent **ethnic disparities** in treatment and monitoring.


Black and mixed ethnic groups remain **least likely** to get optimal cholesterol care.



CHRONIC KIDNEY DISEASE (CKD)


Key finding 7:

52.4% of CKD patients had urine ACR tests in past 12 months (**up 13.5% points since June 2023**). Monitoring for kidney damage is improving – but **nearly half** of CKD patients are still not tested annually.



Key finding 8:

71.5% of people living with CKD + hypertension + proteinuria are treated with RAS antagonists.



OPPORTUNITIES

Key finding 9:

Missed diagnosis remains a major risk – **over 1 million** patients may have not been properly coded which could result in **a possible missed diagnosis** for hypertension, CKD or diabetes.



Key finding 10:

48.3% of patients with CVD met NICE recommended cholesterol targets. Among patients with CHD **80.2%** had blood pressure within the appropriate treatment threshold.

